Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
QNCX
QNCX | US
1.05
USD-0.06
-5.41%
QNCX | US
About QNCX
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
1.05
Open
1.10
High
1.11
Low
1.05
Quince Therapeutics Inc. a preclinical stage biopharmaceutical company develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004 a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme Inc. and changed its name to Quince Therapeutics Inc. in August 2022. Quince Therapeutics Inc. was incorporated in 2012 and is headquartered in South San Francisco California.
View LessQNCX | US
Risk
81.7
Sharpe
-0.27
Luna's Score
39/100
Recommendation
Sell
Luna says (QNCX | US)
What's Working
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
76.7%1 month
81.7%3 months
214.3%6 months
498.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.73
Debt to equity
0.31
Debt to assets
0.11
Ent. to EBITDA
1.44
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-29.13M
MarketCap
45.44M
MarketCap(USD)
45.44M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-79.38
Short ratio
20.83
Short perc.
4.80
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.32
Range1M
0.56
Range3M
1.45
Volumes: Market Activity
Rel. volume
0.31
Price X volume
661.37K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.44 | - | Expensive |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.73 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 214.26 | - | Riskier |
| Debt to Equity | 0.31 | -1.23 | Expensive |
| Debt to Assets | 0.11 | 0.25 | Cheaper |
| Market Cap | 45.44M | - | Emerging |
